Evaluation of biomarkers of NAFLD in a cohort of morbidly obese patients

Journal of Nutrition and Metabolism

Volumn 2011, Issue , 2011, Pages

  Kälsch, Julia ^a   Bechmann, Lars P ^a   Kälsch, Hagen ^a   Schlattjan, Martin ^a   Erhard, Jochen ^b   Gerken, Guido ^a   Canbay, Ali ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Evangelisches Krankenhaus Dinslaken   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872347511     PISSN: 20900724     EISSN: 20900732     Source Type: Journal    
DOI: 10.1155/2011/369168     Document Type: Article

References (27)

1. Feldstein A. E., feldsta@ccf.org Novel insights into the pathophysiology of nonalcoholic fatty liver disease. Seminars in Liver Disease 2010 30 4 391 401 10.1055/s-0030-1267539
2. Cheung O., Sanyal A. J., Abnormalities of lipid metabolism in nonalcoholic fatty liver disease. Seminars in Liver Disease 2008 28 4 351 359 2-s2.0-56649085036 10.1055/s-0028-1091979
3. Ertle J., Dechêne A., Sowa J. P., Penndorf V., Herzer K., Kaiser G., Schlaak J. F., Gerken G., Syn W. K., Canbay A., ali.canbay@uni-due.de Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. International Journal of Cancer 2011 128 10 2436 2443 10.1002/ijc.25797
4. Feldstein A. E., Canbay A., Angulo P., Taniai M., Burgart L. J., Lindor K. D., Gores G. J., Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 2003 125 2 437 443 2-s2.0-0042165989 10.1016/S0016-5085(03)00907-7 (Pubitemid 36929425)
5. Wieckowska A., Zein N. N., Yerian L. M., Lopez A. R., McCullough A. J., Feldstein A. E., In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology 2006 44 1 27 33 2-s2.0-33745904468 10.1002/hep.21223 (Pubitemid 44049136)
6. Yilmaz Y., Dolar E., Ulukaya E., Akgoz S., Keskin M., Kiyici M., Aker S., Yilmaztepe A., Gurel S., Gulten M., Nak S. G., Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World Journal of Gastroenterology 2007 13 6 837 844 2-s2.0-33947528311 (Pubitemid 46470292)
7. Feldstein A. E., Wieckowska A., Lopez A. R., Liu Y. C., Zein N. N., McCullough A. J., Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009 50 4 1072 1078 2-s2.0-70350046669 10.1002/hep.23050
8. McHutchison J. G., jmchutchison@scrippsclinic.com Blatt L. M., de Medina M., Craig J. R., Conrad A., Schiff E. R., Tong M. J., Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Journal of Gastroenterology and Hepatology 2000 15 8 945 951 10.1046/j.1440-1746.2000.02233.x
9. Nobili V., nobili66@yahoo.it Alisi A., Torre G., De Vito R., Pietrobattista A., Morino G., De Ville De Goyet J., Bedogni G., Pinzani M., Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Translational Research 2010 156 4 229 234 10.1016/j.trsl.2010.05. 008
10. Kleiner D. E., Brunt E. M., Van Natta M., Behling C., Contos M. J., Cummings O. W., Ferrell L. D., Liu Y. C., Torbenson M. S., Unalp-Arida A., Yeh M., McCullough A. J., Sanyal A. J., Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005 41 6 1313 1321 2-s2.0-20044374023 10.1002/hep.20701 (Pubitemid 40770284)
11. NLM,. NCBI, Bethesda, Md, USA, 2011, http://www.pubmed.gov
12. Canbay A., Friedman S., Gores G. J., Apoptosis: the nexus of liver injury and fibrosis. Hepatology 2004 39 2 273 278 2-s2.0-1242336980 10.1002/hep.20051 (Pubitemid 38222163)
13. Witek R. P., Stone W. C., Karaca F. G., Syn W. K., Pereira T. A., Agboola K. M., Omenetti A., Jung Y., Teaberry V., Choi S. S., Guy C. D., Pollard J., Charlton P., Diehl A. M., Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis. Hepatology 2009 50 5 1421 1430 2-s2.0-72949123737 10.1002/hep.23167
14. Seeff L. B., Everson G. T., Morgan T. R., Curto T. M., Lee W. M., Ghany M. G., Shiffman M. L., Fontana R. J., Di Bisceglie A. M., Bonkovsky H. L., Dienstag J. L., Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clinical Gastroenterology and Hepatology 2010 8 10 877 883 2-s2.0-77952535634 10.1016/j.cgh.2010.03.025
15. Harwood J., Bishop P., Liu H., Nowicki M., mnowicki@ped.umsmed.edu Safety of blind percutaneous liver biopsy in obese children a retrospective analysis. Journal of Clinical Gastroenterology 2010 44 10 e253 e255 10.1097/MCG. 0b013e3181cf8358
16. Ratziu V., Charlotte F., Heurtier A., Gombert S., Giral P., Bruckert E., Grimaldi A., Capron F., Poynard T., Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005 128 7 1898 1906 2-s2.0-20444443042 10.1053/j.gastro.2005.03.084 (Pubitemid 40824701)
17. Diab D. L., Yerian L., Schauer P., Kashyap S. R., Lopez R., Hazen S. L., Feldstein A. E., Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clinical Gastroenterology and Hepatology 2008 6 11 1249 1254 2-s2.0-55149102644 10.1016/j.cgh.2008.07.016
18. Bechmann L. P., Gieseler R. K., Sowa J. P., Kahraman A., Erhard J., Wedemeyer I., Emons B., Jochum C., Feldkamp T., Gerken G., Canbay A., Apoptosis is associated with CD36/fatty acid translocase upregulation in non-alcoholic steatohepatitis. Liver International 2010 30 6 850 859 2-s2.0-77954363354 10.1111/j.1478-3231.2010.02248.x
19. Tabuchi M., Tomioka K., Kawakami T., Murakami Y., Hiramatsu M., Itoshima T., Sugawara S., Kawashima A., Okita M., mokita@cc.nara-wu.ac.jp Tsukamoto I., Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). Journal of Nutritional Science and Vitaminology 2010 56 5 271 278 10.3177/jnsv.56.271
20. Tan S., Bechmann L. P., Benson S., Dietz T., Eichner S., Hahn S., Janssen O. E., Lahner H., Gerken G., Mann K., Canbay A., Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism 2010 95 1 343 348 2-s2.0-75149156934 10.1210/jc.2009-1834
21. Tamimi T. I. A. R., Elgouhari H. M., Alkhouri N., Yerian L. M., Berk M. P., Lopez R., Schauer P. R., Zein N. N., Feldstein A. E., feldsta@ccf.org An apoptosis panel for nonalcoholic steatohepatitis diagnosis. Journal of Hepatology 2011 54 6 1224 1229 10.1016/j.jhep.2010.08.023
22. Fitzpatrick E., emer.fitzpatrick@kcl.ac.uk Mitry R. R., Quaglia A., Hussain M. J., DeBruyne R., Dhawan A., Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. Journal of Pediatric Gastroenterology and Nutrition 2010 51 4 500 506 10.1097/MPG.0b013e3181e376be
23. Gieseler R. K., Marquitan G., Schlattjan M., Hepatocyte apoptotic bodies encasing nonstructural HCV proteins amplify hepatic stellate cell activation: implications for chronic hepatitis C. Journal of Viral Hepatitis. In press
24. Canbay A., Feldstein A. E., Higuchi H., Werneburg N., Grambihler A., Bronk S. F., Gores G. J., Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 2003 38 5 1188 1198 2-s2.0-0142151769 10.1053/jhep.2003.50472 (Pubitemid 37314827)
25. Castéra L., Foucher J., Bernard P. H., Carvalho F., Allaix D., Merrouche W., Couzigou P., De Lédinghen V., Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010 51 3 828 835 2-s2.0-77950619459 10.1002/hep.23425
26. Martínez S. M., Crespo G., Navasa M., Forns X., xforns@clinic.ub.es Noninvasive assessment of liver fibrosis. Hepatology 2011 53 1 325 335 10.1002/hep.24013
27. Ratziu V., Giral P., Munteanu M., Messous D., Mercadier A., Bernard M., Morra R., Imbert-Bismut F., Bruckert E., Poynard T., Screening for liver disease using non-invasive biomarkers (fibrotest, steatotest and nashtest) in patients with hyperlipidaemia. Alimentary Pharmacology and Therapeutics 2007 25 2 207 218 2-s2.0-33846015006 10.1111/j.1365-2036.2006.03182.x (Pubitemid 46046377)